# SKIPPirr (NCT05663866)

> Premedication to Reduce Amivantamab Associated Infusion Related Reactions

No report yet. It can be ordered.

- Indication: post-osimertinib EGFRm NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05663866
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Dexamethasone; Montelukast; Methotrexate; Amivantamab; Lazertinib
- Enrollment: 68
- Primary outcome: Percentage of Participants With Infusion-related Reactions (IRRs) at Cycle 1 Day 1

## Indexed commentary on SKIPPirr so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 7 YouTube videos
- 7 posts on X
- 4 podcast episodes

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=skippirr-nct05663866

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05663866", "email": "<work email>"}; the inbox owner confirms by the emailed link.
